Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells

Hrabeta,Jan; Groh,Tomas; Khalil,Mohamed  Ashraf; Poljakova,Jitka; Adam,Vojtech; Kizek,Rene; Uhlik,Jiri; Doktorova,Helena; Cerna,Tereza; Frei,Eva; Stiborova,Marie; Eckschlager,Tomas

doi:10.3892/ijo.2015.3066

Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells

Authors:
- Jan Hrabeta
- Tomas Groh
- Mohamed Ashraf Khalil
- Jitka Poljakova
- Vojtech Adam
- Rene Kizek
- Jiri Uhlik
- Helena Doktorova
- Tereza Cerna
- Eva Frei
- Marie Stiborova
- Tomas Eckschlager
View Affiliations

Affiliations: Department of Pediatric Hematology and Oncology, Second Medical School, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic, Department of Biochemistry, Faculty of Science, Charles University, 128 40 Prague, Czech Republic, Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, 613 00 Brno, Czech Republic, Department of Histology and Embryology, Second Medical School, Charles University, 150 06 Prague, Czech Republic, Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), D-69 120 Heidelberg, Germany
Published online on: June 29, 2015 https://doi.org/10.3892/ijo.2015.3066
Pages: 971-980

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is the most common cancer in infants and the fourth most common cancer in children. Aggressive cell growth and chemoresistance are notorious obstacles in neuroblastoma therapy. Exposure to the anticancer drug ellipticine inhibits efficiently growth of neuroblastoma cells and induces apoptosis in these cells. However, ellipticine induced resistance in these cells. The upregulation of a vacuolar (V)-ATPase gene is one of the factors associated with resistance development. In accordance with this finding, we found that levels of V-ATPase protein expression are higher in the ellipticine-resistant UKF-NB-4ELLI line than in the parental ellipticine-sensitive UKF-NB-4 cell line. Treatment of ellipticine-sensitive UKF-NB-4 and ellipticine-resistant UKF-NB-4ELLI cells with ellipticine-induced cytoplasmic vacuolization and ellipticine is concentrated in these vacuoles. Confocal microscopy and staining of the cells with a lysosomal marker suggested these vacuoles as lysosomes. Transmission electron microscopy and no effect of an autophagy inhibitor wortmannin ruled out autophagy. Pretreatment with a V-ATPase inhibitor bafilomycin A and/or the lysosomotropic drug chloroquine prior to ellipticine enhanced the ellipticine‑mediated apoptosis and decreased ellipticine-resistance in UKF-NB-4ELLI cells. Moreover, pretreatment with these inhibitors increased formation of ellipticine-derived DNA adducts, one of the most important DNA-damaging mechanisms responsible for ellipticine cytotoxicity. In conclusion, resistance to ellipticine in the tested neuroblastoma cells is associated with V-ATPase-mediated vacuolar trapping of this drug, which may be decreased by bafilomycin A and/or chloroquine.

View Figures

View References

1	Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003. View Article : Google Scholar : PubMed/NCBI
2	Schwab M, Westermann F and Hero Band Berthold F: Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol. 4:472–480. 2003. View Article : Google Scholar : PubMed/NCBI
3	Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM: Wilms' tumor and neuroblastoma. Acta Paediatr (Suppl). 93:78–85. 2004. View Article : Google Scholar
4	Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J and Cinatl J Jr: Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol. 27:1029–1037. 2005.PubMed/NCBI
5	Michaelis M, Klassert D, Barth S, Suhan T, Breitling R, Mayer B, Hinsch N, Doerr HW, Cinatl J and Cinatl J Jr: Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mol Cancer. 8:802009. View Article : Google Scholar : PubMed/NCBI
6	Stiborová M, Rupertová M and Frei E: Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. Biochim Biophys Acta. 1814:175–185. 2011. View Article : Google Scholar
7	Stiborová M and Frei E: Ellipticines as DNA-targeted chemo-therapeutics. Curr Med Chem. 21:575–591. 2014. View Article : Google Scholar
8	Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Martínek V, Kizek R and Stiborová M: The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol. 77:1466–1479. 2009. View Article : Google Scholar : PubMed/NCBI
9	Poljakova J, Hrebackova J, Dvorakova M, Moserova M, Eckschlager T, Hrabeta J, Göttlicherova M, Kopejtkova B, Frei E, Kizek R, et al: Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. Neuro Endocrinol Lett. 32(Suppl 1): 101–116. 2011.PubMed/NCBI
10	Stiborová M, Eckschlager T, Poljaková J, Hrabĕta J, Adam V, Kizek R and Frei E: The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem. 19:4218–4238. 2012. View Article : Google Scholar : PubMed/NCBI
11	Stiborova M, Poljakova J, Mrizova I, et al: Expression levels of enzymes metabolizing an anticancer drug ellipticine determined by electromigration assays influence its cytotoxicity to cancer cells - a comparative study. Int J Electrochem Sci. 9:5675–5689. 2014.
12	Stiborová M, Bieler CA, Wiessler M and Frei E: The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol. 62:1675–1684. 2001. View Article : Google Scholar
13	Stiborová M, Sejbal J, Borek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudecek J, Wiessler M, et al: The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 64:8374–8380. 2004. View Article : Google Scholar : PubMed/NCBI
14	Stiborova M, Rupertova M, Schmeiser HH and Frei E: Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 150:13–23. 2006. View Article : Google Scholar : PubMed/NCBI
15	Stiborová M, Poljaková J, Ryslavá H, Dracínský M, Eckschlager T and Frei E: Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer. 120:243–251. 2007. View Article : Google Scholar
16	Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E and Stiborova M: Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol Ther. 133:26–39. 2012. View Article : Google Scholar
17	Procházka P, Libra A, Zemanová Z, Hřebačková J, Poljaková J, Hrabĕta J, Bunček M, Stiborová M and Eckschlager T: Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Sci. 103:334–341. 2012. View Article : Google Scholar
18	Marshansky V, Rubinstein JL and Grüber G: Eukaryotic V-ATPase: Novel structural findings and functional insights. Biochim Biophys Acta. 1837:857–879. 2014. View Article : Google Scholar : PubMed/NCBI
19	Maxfield FR and McGraw TE: Endocytic recycling. Nat Rev Mol Cell Biol. 5:121–132. 2004. View Article : Google Scholar : PubMed/NCBI
20	Goldman SDB, Funk RS, Rajewski RA and Krise JP: Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis. 1:1445–1459. 2009. View Article : Google Scholar
21	Coutinho MF, Prata MJ and Alves S: Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction. Mol Genet Metab. 105:542–550. 2012. View Article : Google Scholar : PubMed/NCBI
22	Simon S, Roy D and Schindler M: Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA. 91:1128–1132. 1994. View Article : Google Scholar : PubMed/NCBI
23	Mahoney BP, Raghunand N, Baggett B and Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 66:1207–1218. 2003. View Article : Google Scholar : PubMed/NCBI
24	Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, et al: Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia. 22:1576–1586. 2008. View Article : Google Scholar : PubMed/NCBI
25	Spugnini EP, Citro G and Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: A novel anticancer strategy. J Exp Clin Cancer Res. 29:442010. View Article : Google Scholar : PubMed/NCBI
26	Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ and Richardson DR: P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 288:31761–31771. 2013. View Article : Google Scholar : PubMed/NCBI
27	Frei E, Bieler CA, Arlt VM, Wiessler M and Stiborová M: Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol. 64:289–295. 2002. View Article : Google Scholar : PubMed/NCBI
28	Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J and Stiborová M: DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 252:270–279. 2007. View Article : Google Scholar : PubMed/NCBI
29	Martinkova E, Dontenwill M, Frei E and Stiborova M: Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett. 30(Suppl 1): 60–66. 2009.PubMed/NCBI
30	Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S and Dontenwill M: alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer. 127:1240–1248. 2010. View Article : Google Scholar : PubMed/NCBI
31	Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M and Frei E: DNA adduct formation by the anticancer drug ellipticine in rats determined by ³²P postlabeling. Int J Cancer. 107:885–890. 2003. View Article : Google Scholar
32	Stiborová M, Rupertová M, Aimová D, Ryslavá H and Frei E: Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology. 236:50–60. 2007. View Article : Google Scholar : PubMed/NCBI
33	Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH and Frei E: Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol. 226:318–327. 2008. View Article : Google Scholar
34	Hunziker W and Geuze HJ: Intracellular trafficking of lysosomal membrane proteins. Bioessays. 18:379–389. 1996. View Article : Google Scholar : PubMed/NCBI
35	Oeste CL, Seco E, Patton WF, Boya P and Pérez-Sala D: Interactions between autophagic and endo-lysosomal markers in endothelial cells. Histochem Cell Biol. 139:659–670. 2013. View Article : Google Scholar
36	Garbett NC and Graves DE: Extending nature's leads: The anti-cancer agent ellipticine. Curr Med Chem Anticancer Agents. 4:149–172. 2004. View Article : Google Scholar : PubMed/NCBI
37	Wu Y, Sadatmousavi P, Wang R, Lu S, Yuan YF and Chen P: Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo. Int J Nanomed. 7:3221–3233. 2012.
38	Bowman EJ, Siebers A and Altendorf K: Bafilomycins: A class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA. 85:7972–7976. 1988. View Article : Google Scholar : PubMed/NCBI
39	Huss M and Wieczorek H: Inhibitors of V-ATPases: Old and new players. J Exp Biol. 212:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
40	Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, Schmidt RE and Roth KA: Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol. 69:1125–1136. 2006. View Article : Google Scholar : PubMed/NCBI
41	Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS and Gillies RJ: pH and drug resistance. I Functional expression of plasmalemmal V-type H⁺-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 57:1037–1046. 1999. View Article : Google Scholar
42	Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, et al: Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 93:869–874. 2001. View Article : Google Scholar : PubMed/NCBI
43	Huang L, Lu Q, Han Y, Li Z, Zhang Z and Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 7:1802012. View Article : Google Scholar : PubMed/NCBI
44	Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, Pirola L, Vanhaesebroeck B, Waterfield MD and Panayotou G: Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol. 16:1722–1733. 1996.PubMed/NCBI
45	Arcaro A and Wymann MP: Wortmannin is a potent phospha-tidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J. 296:297–301. 1993. View Article : Google Scholar
46	Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelárová H and Meijer AJ: The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem. 243:240–246. 1997. View Article : Google Scholar : PubMed/NCBI
47	Tanida I, Ueno T and Kominami E: LC3 and sutophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar
48	Solomon VR and Lee H: Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol. 625:220–233. 2009. View Article : Google Scholar : PubMed/NCBI